PL2411376T3 - Inhibitory nf-kb - Google Patents

Inhibitory nf-kb

Info

Publication number
PL2411376T3
PL2411376T3 PL10724601T PL10724601T PL2411376T3 PL 2411376 T3 PL2411376 T3 PL 2411376T3 PL 10724601 T PL10724601 T PL 10724601T PL 10724601 T PL10724601 T PL 10724601T PL 2411376 T3 PL2411376 T3 PL 2411376T3
Authority
PL
Poland
Prior art keywords
inhibitors
Prior art date
Application number
PL10724601T
Other languages
English (en)
Inventor
Jie Zhang
D Robert Sliskovic
Charles E Ducker
Original Assignee
Profectus Biosciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Profectus Biosciences Inc filed Critical Profectus Biosciences Inc
Publication of PL2411376T3 publication Critical patent/PL2411376T3/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D303/00—Compounds containing three-membered rings having one oxygen atom as the only ring hetero atom
    • C07D303/02—Compounds containing oxirane rings
    • C07D303/36—Compounds containing oxirane rings with hydrocarbon radicals, substituted by nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/06—Free radical scavengers or antioxidants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
    • C07D407/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings
    • C07D407/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Virology (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Communicable Diseases (AREA)
  • Diabetes (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Neurosurgery (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Rheumatology (AREA)
  • Emergency Medicine (AREA)
  • Vascular Medicine (AREA)
  • AIDS & HIV (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Pain & Pain Management (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Hospice & Palliative Care (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Obesity (AREA)
PL10724601T 2009-03-27 2010-03-25 Inhibitory nf-kb PL2411376T3 (pl)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US16425609P 2009-03-27 2009-03-27
US25509609P 2009-10-27 2009-10-27
US26502609P 2009-11-30 2009-11-30
PCT/US2010/028610 WO2010111460A1 (en) 2009-03-27 2010-03-25 Inhibitors of nf-kb
EP20100724601 EP2411376B1 (en) 2009-03-27 2010-03-25 Inhibitors of nf-kb

Publications (1)

Publication Number Publication Date
PL2411376T3 true PL2411376T3 (pl) 2015-10-30

Family

ID=42324526

Family Applications (1)

Application Number Title Priority Date Filing Date
PL10724601T PL2411376T3 (pl) 2009-03-27 2010-03-25 Inhibitory nf-kb

Country Status (14)

Country Link
US (1) US8629164B2 (pl)
EP (1) EP2411376B1 (pl)
JP (1) JP5719344B2 (pl)
CN (1) CN102414190B (pl)
CA (1) CA2755910C (pl)
DK (1) DK2411376T3 (pl)
ES (1) ES2540351T3 (pl)
HR (1) HRP20150777T1 (pl)
PL (1) PL2411376T3 (pl)
PT (1) PT2411376E (pl)
SI (1) SI2411376T1 (pl)
SM (1) SMT201500178B (pl)
TW (1) TW201038561A (pl)
WO (1) WO2010111460A1 (pl)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20140380387A1 (en) * 2011-12-12 2014-12-25 Samsung Electronics Co., Ltd. System, apparatus and method for utilizing a multimedia service
CN103961687A (zh) * 2013-02-05 2014-08-06 中国人民解放军军事医学科学院放射与辐射医学研究所 G蛋白偶联受体相互作用蛋白2在制备抗炎症药物中的应用
CN106645457B (zh) * 2016-10-13 2019-03-15 深圳万和制药有限公司 水杨酸酰胺衍生物dhmeq软膏剂组合物及分析方法

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2393883C (en) * 1999-08-11 2010-07-06 Tomio Takeuchi Salicylamide derivatives
JP2002193938A (ja) * 2000-12-01 2002-07-10 Bayer Ag 4−アリールピリジン誘導体
KR20060053824A (ko) 2002-06-26 2006-05-22 시그널 크리에이션, 아이엔씨 NF-κB 저해제를 포함하는 의약조성물
CN1774429A (zh) * 2003-02-14 2006-05-17 学校法人庆应义塾 医药组合物
AU2004210789A1 (en) * 2003-02-14 2004-08-26 Signal Creation Inc. Pharmaceutical composition
JP2008259494A (ja) * 2007-03-05 2008-10-30 Keio Gijuku (±)−dhmeqの酵素光学分割法および(−)−dhmeqの製造方法
WO2010127058A1 (en) 2009-05-01 2010-11-04 Profectus Biosciences, Inc. Benzamide and naphthamide derivatives inhibiting nuclear factor- kap pa (b) - (nf-kb)
EP2443103A1 (en) 2009-06-18 2012-04-25 Profectus Biosciences, Inc. Oxabicyclo [4.1.o]hept-b-en-s-ylcarbamoyl derivatives inhibiting the nuclear factor-kappa(b) - (nf-kb)

Also Published As

Publication number Publication date
HRP20150777T1 (hr) 2015-09-11
ES2540351T3 (es) 2015-07-09
EP2411376B1 (en) 2015-04-22
PT2411376E (pt) 2015-09-14
CA2755910C (en) 2016-11-01
JP5719344B2 (ja) 2015-05-20
CA2755910A1 (en) 2010-09-30
SMT201500178B (it) 2015-09-07
EP2411376A1 (en) 2012-02-01
US20120015952A1 (en) 2012-01-19
DK2411376T3 (en) 2015-07-06
JP2012521998A (ja) 2012-09-20
WO2010111460A1 (en) 2010-09-30
TW201038561A (en) 2010-11-01
US8629164B2 (en) 2014-01-14
CN102414190B (zh) 2015-06-03
SI2411376T1 (sl) 2015-10-30
CN102414190A (zh) 2012-04-11

Similar Documents

Publication Publication Date Title
EP2440054A4 (en) PYRIDILTRIA INHIBITOR OF HEDGEHOG SIGNALING
IL219049A (en) Antisense inhibitors
IL208136A0 (en) Substituted dihydropyrazolones as inhibitors of hif-prolyl-4-hydroxylases
EP2389068A4 (en) HEMGE OF THE HEDGEHOG SIGNAL PATH
IL218018A0 (en) Novel n-substituted-pyrrolidines as inhibitors of mdm2-p-53 interactions
ZA201206456B (en) Uses of dgati inhibitors
EP2519508A4 (en) METALLO ENZYME INHIBITOR COMPOUNDS
IL212119A0 (en) Alkylcyclohexylethers of dihydrotetraazabenzoazulenes
IL220187A0 (en) Inhibitors of sphingosine kinase
IL215645A0 (en) Inhibitors of cognitive decline
IL217833A0 (en) Inhibitors of cognitive decline
EP2521451A4 (en) INHIBITORS OF THE HEDGEHOG PATH
SI2506840T1 (sl) Uporabe zaviralcev faktorja, ki jih inducira hiposkija
ZA201004765B (en) Inhibitors of iap
GB0901898D0 (en) Dual calpain-ros inhibitors
EP2496230A4 (en) INHIBITORS OF IRE-1 ALPHA
IL217756A0 (en) Inhibitors of jnk
SI2411376T1 (sl) INHIBITORJI NF-kB
GB0916010D0 (en) JMJD2 demethylase inhibitors
GB0901900D0 (en) Dual calpain-ros inhibitors
IL215486A0 (en) Compositions of cholinesterase inhibitors
GB0908609D0 (en) New use of isoQC inhibitors
GB0903650D0 (en) Glyoalase inhibitors
GB0902661D0 (en) Inhibitors
GB0903651D0 (en) Inhibitors of glyoxalase